This Bioengineering Research Partnership (BRP) will exploit emerging advances in semiconductor nanocrystal-based biomedical imaging to probe the tumor microenvironment and to develop therapeutic and diagnostic strategies. To accomplish this, we have assembled a multidisciplinary team of scientists and engineers at the Massachusetts General Hospital (MGH) and Massachusetts Institute of Technology (MIT) with a successful track record of basic and translational research. Over the past decade, this team has provided unprecedented insight into the nature of transport barriers in tumors (Nature Reviews Cancer, 2002). These exciting scientific findings resulted from innovations in intravital imaging (Nature Medicine, 1997, 2001, 2003, 2004), from exploiting molecular tools and quantum dot technology (Nature Medicine, 2005), and from the development of unique in vitro, in vivo, and mathematical models (PNAS, 1998, JCO, 2006). Our discoveries to date have led to novel strategies for improving drug delivery to tumors (Science, 2005). Development Cores led by M. Bawendi (an early pioneer of quantum dots) and D. Nocera at MIT are the corner stone of this BRP. They will develop novel nanocrystal (quantum dot) constructs, biosensors, and immunoconjugates which are not only essential for all three projects in this BRP but also provide a new direction in nanocrystal based bio-imaging by creating "smart" nanocrystal probes of chemical and morphological environment. In Project 1, led by D. Fukumura and L. Munn, we aim to develop "design rules" for nanoparticles and apply these rules to make "smart" nanoparticles that, by changing their size and charge, can circumvent tumor barriers. In Project 2, led by R.K.Jain, we seek to map metabolic microenvironment of tumors with novel nanocrystal based biosensors and improve pH-sensitive chemotherapy and oxygen-sensitive radiation therapy. In Project 3, led by D. Duda and Y. Boucher, we harness the multiplexing capabilities of nanocrystal immunoconjugate probes and biosensors to develop in vivo multi-cell molecular and functional phenotyping techniques and establish a novel treatment strategy based on targeting stromal cells in tumors. A high level of scientific interaction among the three Projects, two Development Cores and four scientific Cores is a major strength of the BRP - as documented in joint publications by Project and Core leaders. Each Project will rely on multi-photon microscopy, mathematical modeling, and statistical support provided by Core A;cutting-edge molecular, cellular and histological expertise provided by Core B;superb surgical and animal support provided by Core C;and administrative support provided by Core D. We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Wolpert, Mary K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Duda, Dan G; Ancukiewicz, Marek; Isakoff, Steven J et al. (2014) Seeds and soil: unraveling the role of local tumor stroma in distant metastasis. J Natl Cancer Inst 106:
Chen, Ou; Riedemann, Lars; Etoc, Fred et al. (2014) Magneto-fluorescent core-shell supernanoparticles. Nat Commun 5:5093
Lemon, Christopher M; Curtin, Peter N; Somers, Rebecca C et al. (2014) Metabolic tumor profiling with pH, oxygen, and glucose chemosensors on a quantum dot scaffold. Inorg Chem 53:1900-15
Jain, Rakesh K (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605-22
Jain, Rakesh K; Martin, John D; Stylianopoulos, Triantafyllos (2014) The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng 16:321-46
Chen, Yunching; Huang, Yuhui; Reiberger, Thomas et al. (2014) Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59:1435-47
Stylianopoulos, Triantafyllos; Jain, Rakesh K (2013) Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A 110:18632-7
Duda, Dan G; Munn, Lance L; Jain, Rakesh K (2013) Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst 105:762-5
Huang, Yuhui; Stylianopoulos, Triantafyllos; Duda, Dan G et al. (2013) Benefits of vascular normalization are dose and time dependent--letter. Cancer Res 73:7144-6
Wei, He; Bruns, Oliver T; Chen, Ou et al. (2013) Compact zwitterion-coated iron oxide nanoparticles for in vitro and in vivo imaging. Integr Biol (Camb) 5:108-14

Showing the most recent 10 out of 83 publications